Oligonucleotide Synthesis Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Oligonucleotide Synthesis Market 

5.1. COVID-19 Landscape: Oligonucleotide Synthesis Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Oligonucleotide Synthesis Market, By Type of Product Synthesized

8.1. Oligonucleotide Synthesis Market, by Type of Product Synthesized

8.1.1. Active Pharmaceutical Ingredients

8.1.1.1. Market Revenue and Forecast  

8.1.2. Finished Dosage Forms

8.1.2.1. Market Revenue and Forecast  

Chapter 9. Global Oligonucleotide Synthesis Market, By Type of Oligonucleotide Synthesized

9.1. Oligonucleotide Synthesis Market, by Type of Oligonucleotide Synthesized

9.1.1. Antisense

9.1.1.1. Market Revenue and Forecast  

9.1.2. DNA

9.1.2.1. Market Revenue and Forecast  

9.1.3. siRNA

9.1.3.1. Market Revenue and Forecast  

9.1.4. Other Oligonucleotides

9.1.4.1. Market Revenue and Forecast  

Chapter 10. Global Oligonucleotide Synthesis Market, By Company Size

10.1. Oligonucleotide Synthesis Market, by Company Size

10.1.1. Small

10.1.1.1. Market Revenue and Forecast  

10.1.2. Mid-sized

10.1.2.1. Market Revenue and Forecast  

10.1.3. Large and Very Large

10.1.3.1. Market Revenue and Forecast  

Chapter 11. Global Oligonucleotide Synthesis Market, By Scale of Operation

11.1. Oligonucleotide Synthesis Market, by Scale of Operation

11.1.1. Clinical

11.1.1.1. Market Revenue and Forecast  

11.1.2. Commercial

11.1.2.1. Market Revenue and Forecast  

Chapter 12. Global Oligonucleotide Synthesis Market, By Therapeutic Area

12.1. Oligonucleotide Synthesis Market, by Therapeutic Area

12.1.1. Cardiovascular Disorders

12.1.1.1. Market Revenue and Forecast  

12.1.2. Genetic Disorders

12.1.2.1. Market Revenue and Forecast  

12.1.3. Liver Disorders

12.1.3.1. Market Revenue and Forecast  

12.1.4. Rare Diseases

12.1.4.1. Market Revenue and Forecast  

12.1.5. Other Disorders

12.1.5.1. Market Revenue and Forecast  

Chapter 13. Global Oligonucleotide Synthesis Market, By End-Users

13.1. Oligonucleotide Synthesis Market, by End-Users

13.1.1. Pharmaceutical/Biopharmaceutical Companies

13.1.1.1. Market Revenue and Forecast  

13.1.2. Academic and Research Institutes

13.1.2.1. Market Revenue and Forecast  

13.1.3. Hospitals

13.1.3.1. Market Revenue and Forecast  

Chapter 14. Global Oligonucleotide Synthesis Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.1.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.1.3. Market Revenue and Forecast, by Company Size  

14.1.4. Market Revenue and Forecast, by Scale of Operation  

14.1.5. Market Revenue and Forecast, by Therapeutic Area  

14.1.6. Market Revenue and Forecast, by End-Users  

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.1.7.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.1.7.3. Market Revenue and Forecast, by Company Size  

14.1.7.4. Market Revenue and Forecast, by Scale of Operation  

14.1.8. Market Revenue and Forecast, by Therapeutic Area  

14.1.8.1. Market Revenue and Forecast, by End-Users   

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.1.9.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.1.9.3. Market Revenue and Forecast, by Company Size  

14.1.9.4. Market Revenue and Forecast, by Scale of Operation  

14.1.10. Market Revenue and Forecast, by Therapeutic Area  

14.1.11. Market Revenue and Forecast, by End-Users  

14.2. Europe

14.2.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.2.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.2.3. Market Revenue and Forecast, by Company Size  

14.2.4. Market Revenue and Forecast, by Scale of Operation   

14.2.5. Market Revenue and Forecast, by Therapeutic Area  

14.2.6. Market Revenue and Forecast, by End-Users  

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.2.8.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.2.8.3. Market Revenue and Forecast, by Company Size  

14.2.9. Market Revenue and Forecast, by Scale of Operation   

14.2.10. Market Revenue and Forecast, by Therapeutic Area  

14.2.10.1. Market Revenue and Forecast, by End-Users   

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.2.11.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.2.11.3. Market Revenue and Forecast, by Company Size  

14.2.12. Market Revenue and Forecast, by Scale of Operation  

14.2.13. Market Revenue and Forecast, by Therapeutic Area  

14.2.14. Market Revenue and Forecast, by End-Users  

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.2.15.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.2.15.3. Market Revenue and Forecast, by Company Size  

14.2.15.4. Market Revenue and Forecast, by Scale of Operation  

14.2.16. Market Revenue and Forecast, by Therapeutic Area  

14.2.16.1. Market Revenue and Forecast, by End-Users  

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.2.17.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.2.17.3. Market Revenue and Forecast, by Company Size  

14.2.17.4. Market Revenue and Forecast, by Scale of Operation  

14.2.18. Market Revenue and Forecast, by Therapeutic Area  

14.2.18.1. Market Revenue and Forecast, by End-Users  

14.3. APAC

14.3.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.3.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.3.3. Market Revenue and Forecast, by Company Size  

14.3.4. Market Revenue and Forecast, by Scale of Operation  

14.3.5. Market Revenue and Forecast, by Therapeutic Area  

14.3.6. Market Revenue and Forecast, by End-Users  

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.3.7.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.3.7.3. Market Revenue and Forecast, by Company Size  

14.3.7.4. Market Revenue and Forecast, by Scale of Operation  

14.3.8. Market Revenue and Forecast, by Therapeutic Area  

14.3.9. Market Revenue and Forecast, by End-Users  

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.3.10.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.3.10.3. Market Revenue and Forecast, by Company Size  

14.3.10.4. Market Revenue and Forecast, by Scale of Operation  

14.3.11. Market Revenue and Forecast, by Therapeutic Area  

14.3.11.1. Market Revenue and Forecast, by End-Users  

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.3.12.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.3.12.3. Market Revenue and Forecast, by Company Size  

14.3.12.4. Market Revenue and Forecast, by Scale of Operation  

14.3.12.5. Market Revenue and Forecast, by Therapeutic Area  

14.3.12.6. Market Revenue and Forecast, by End-Users  

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.3.13.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.3.13.3. Market Revenue and Forecast, by Company Size  

14.3.13.4. Market Revenue and Forecast, by Scale of Operation  

14.3.13.5. Market Revenue and Forecast, by Therapeutic Area  

14.3.13.6. Market Revenue and Forecast, by End-Users  

14.4. MEA

14.4.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.4.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.4.3. Market Revenue and Forecast, by Company Size  

14.4.4. Market Revenue and Forecast, by Scale of Operation  

14.4.5. Market Revenue and Forecast, by Therapeutic Area  

14.4.6. Market Revenue and Forecast, by End-Users  

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.4.7.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.4.7.3. Market Revenue and Forecast, by Company Size  

14.4.7.4. Market Revenue and Forecast, by Scale of Operation  

14.4.8. Market Revenue and Forecast, by Therapeutic Area  

14.4.9. Market Revenue and Forecast, by End-Users  

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.4.10.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.4.10.3. Market Revenue and Forecast, by Company Size  

14.4.10.4. Market Revenue and Forecast, by Scale of Operation  

14.4.11. Market Revenue and Forecast, by Therapeutic Area  

14.4.12. Market Revenue and Forecast, by End-Users  

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.4.13.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.4.13.3. Market Revenue and Forecast, by Company Size  

14.4.13.4. Market Revenue and Forecast, by Scale of Operation  

14.4.13.5. Market Revenue and Forecast, by Therapeutic Area  

14.4.13.6. Market Revenue and Forecast, by End-Users  

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.4.14.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.4.14.3. Market Revenue and Forecast, by Company Size  

14.4.14.4. Market Revenue and Forecast, by Scale of Operation  

14.4.14.5. Market Revenue and Forecast, by Therapeutic Area  

14.4.14.6. Market Revenue and Forecast, by End-Users  

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.5.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.5.3. Market Revenue and Forecast, by Company Size  

14.5.4. Market Revenue and Forecast, by Scale of Operation  

14.5.5. Market Revenue and Forecast, by Therapeutic Area  

14.5.6. Market Revenue and Forecast, by End-Users  

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.5.7.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.5.7.3. Market Revenue and Forecast, by Company Size  

14.5.7.4. Market Revenue and Forecast, by Scale of Operation  

14.5.8. Market Revenue and Forecast, by Therapeutic Area  

14.5.8.1. Market Revenue and Forecast, by End-Users  

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Type of Product Synthesized  

14.5.9.2. Market Revenue and Forecast, by Type of Oligonucleotide Synthesized  

14.5.9.3. Market Revenue and Forecast, by Company Size  

14.5.9.4. Market Revenue and Forecast, by Scale of Operation  

14.5.9.5. Market Revenue and Forecast, by Therapeutic Area  

14.5.9.6. Market Revenue and Forecast, by End-Users  

Chapter 15. Company Profiles

15.1. Agilent Technologies

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Ajinomoto Bio-Pharma Services

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. CordenPharma

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Creative Biolabs

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Ella Biotech

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Eurofins Genomics

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Future synthesis

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Integrated DNA Technologies

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Kaneka Eurogentec

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. LGC Biosearch Technologies

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms